#India #New York #Acurx Pharmaceuticals #DNA Polymerase IIIC #Antibiotic Innovation

Acurx Pharmaceuticals Secures Indian Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, a late-stage biopharmaceutical company listed on NASDAQ under the ticker ACXP, has recently received a significant boost in its innovative efforts through the granting of a patent by the Indian Patent Office. This new patent, awarded in March 2025, focuses on their groundbreaking work with DNA Polymerase IIIC inhibitors, which are part of a new class of small molecule antibiotics aimed at combating difficult-to-treat bacterial infections.

With a robust portfolio of intellectual property, Acurx has made strides in ensuring the protection of their proprietary technologies in the field of antimicrobials. The company has previously secured three patents in the United States, along with patents in Israel and Japan. The addition of the Indian patent marks a critical step in Acurx's strategic plan as they expand their global presence.

Expanding Reach of Antibiotic Solutions

Dr. Robert J. DeLuccia, Executive Chairman of Acurx Pharmaceuticals, expressed enthusiasm regarding the new patent, emphasizing how it aligns with the company's ambition to develop an AI-supported drug discovery platform focused on DNA Polymerase IIIC inhibitors, cited as second-generation antibiotics. He remarked, “Achieving this patent in India adds to our growing number of countries as we further develop our innovative approaches.”

Acurx is advancing its lead DNA Polymerase IIIC inhibitor, which is prepared for Phase 3 trials. This product is specifically designed for the oral treatment of Clostridium difficile infections — a common and severe bacterial infection that poses significant risks in healthcare settings. Furthermore, Acurx's second-generation compounds are intended for systemic absorption, making them suitable for both oral and parenteral uses in treating infections caused by gram-positive bacteria. These include serious pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), and drug-resistant strains of Streptococcus pneumoniae (DRSP), among others.

The urgent need for effective antibiotic treatments is underscored by the prevalence of these resistant strains, prompting Acurx to accelerate its development plans. Their mission resonates especially as they prepare for potential clinical applications against public health threats, including Bacillus anthracis, known as a Category A Bioterrorism threat.

The Road Ahead for Acurx Pharmaceuticals

Acurx continues to prioritize the extensive development of its product pipeline. Their existing candidate, ibezapolstat, is at the forefront, with plans to initiate international clinical trials soon. Besides targeting C. difficile infections, the company is also innovating oral antibiotic treatments for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In parallel, the development of therapies for inhaled anthrax is also on the agenda, further highlighting Acurx's commitment to addressing severe bacterial threats comprehensively.

Acurx's approach sets it apart in an increasingly crowded pharmaceutical landscape, aiming for a Gram-positive selective spectrum (GPSS®) that inhibits bacterial DNA replication via the specific blockage of the DNA polymerase IIIC enzyme. This innovative strategy aims not only to offer new solutions but to significantly impact the treatment landscape for infections that have long posed challenges to healthcare providers globally.

Conclusion

As Acurx Pharmaceuticals positions itself as a leader in antibiotic development, the newly granted patent in India adds an essential layer of strategic advantage. The company’s innovative technologies and commitment to addressing pressing bacterial infections reflect not only a response to current healthcare demands but also a proactive approach to future challenges in infectious diseases. Those interested in learning more about Acurx and their pipeline are encouraged to visit acurxpharma.com for more information.